Robert J. Spiegel Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Robert J. Spiegel.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Robert J. Spiegel. Robert J. Spiegel is Director in Capstone Therapeutics Corp. ($CAPS) and Director in GERON CORP ($GERN) and Director in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Chief Medical Officer in PTC THERAPEUTICS, INC. ($PTCT) and Director in Athenex, Inc. ($ATNX) and Director in Sucampo Pharmaceuticals, Inc. ($SCMP) and Director in Edge Therapeutics, Inc. ($EDGE).
Latest Insider Trading Transactions of Robert J. Spiegel
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ATNX, CAPS, CYCC, GERN, EDGE, PTCT, SCMP
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13 2021 | GERN | GERON CORP | Spiegel Robert J. | Director | Option Exercise | A | 1.39 | 83,000 | 115,370 | 83,000 | |
| Apr 02 2021 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 4,549 | 0 | 119,497 | 114.9 K to 119.5 K (+3.96 %) |
| Jan 11 2021 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 4,520 | 0 | 114,948 | 110.4 K to 114.9 K (+4.09 %) |
| Oct 02 2020 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 4,130 | 0 | 110,428 | 106.3 K to 110.4 K (+3.89 %) |
| Aug 12 2020 | ATNX | Athenex, Inc. | Spiegel Robert J. | Director | Option Exercise | A | 11.40 | 7,292 | 83,129 | 7,292 | |
| Jul 02 2020 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 3,297 | 0 | 106,298 | 103 K to 106.3 K (+3.20 %) |
| Jun 29 2020 | CYCC | Cyclacel Pharmaceu ... | Spiegel Robert J. | Director | Option Exercise | A | 4.70 | 5,200 | 24,440 | 5,200 | |
| Jun 09 2020 | GERN | GERON CORP | Spiegel Robert J. | Director | Option Exercise | A | 1.54 | 83,000 | 127,820 | 83,000 | |
| Apr 01 2020 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 6,039 | 0 | 103,001 | 97 K to 103 K (+6.23 %) |
| Jan 03 2020 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 5,284 | 0 | 96,962 | 91.7 K to 97 K (+5.76 %) |
| Oct 01 2019 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 5,404 | 0 | 91,678 | 86.3 K to 91.7 K (+6.26 %) |
| Jul 01 2019 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 5,097 | 0 | 86,274 | 81.2 K to 86.3 K (+6.28 %) |
| Jun 07 2019 | GERN | GERON CORP | Spiegel Robert J. | Director | Option Exercise | A | 1.38 | 70,000 | 96,600 | 70,000 | |
| May 31 2019 | CYCC | Cyclacel Pharmaceu ... | Spiegel Robert J. | Director | Option Exercise | A | 0.64 | 18,750 | 12,000 | 18,750 | |
| May 31 2019 | CYCC | Cyclacel Pharmaceu ... | Spiegel Robert J. | Director | Option Exercise | A | 0.64 | 18,750 | 12,000 | 18,750 | |
| Apr 01 2019 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 4,329 | 0 | 81,177 | 76.8 K to 81.2 K (+5.63 %) |
| Mar 18 2019 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | M | 0.00 | 10,000 | 0 | 0 | |
| Mar 18 2019 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Buy | M | 0.00 | 10,000 | 0 | 48,661 | 38.7 K to 48.7 K (+25.87 %) |
| Jan 02 2019 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 7,188 | 0 | 76,848 | 69.7 K to 76.8 K (+10.32 %) |
| Sep 28 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 4,084 | 0 | 69,660 | 65.6 K to 69.7 K (+6.23 %) |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Option Exercise | M | 1.94 | 35,000 | 67,900 | 0 | |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Option Exercise | M | 1.10 | 35,000 | 38,500 | 0 | |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Option Exercise | M | 1.41 | 35,000 | 49,350 | 0 | |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Option Exercise | M | 4.91 | 15,000 | 73,650 | 0 | |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Option Exercise | M | 4.91 | 10,000 | 49,100 | 0 | |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Option Exercise | M | 5.29 | 45,000 | 238,050 | 0 | |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Sell | S | 6.85 | 35,000 | 239,750 | 65,576 | 100.6 K to 65.6 K (-34.80 %) |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Buy | M | 1.94 | 35,000 | 67,900 | 100,576 | 65.6 K to 100.6 K (+53.37 %) |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Sell | S | 6.85 | 35,000 | 239,750 | 65,576 | 100.6 K to 65.6 K (-34.80 %) |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Buy | M | 1.10 | 35,000 | 38,500 | 100,576 | 65.6 K to 100.6 K (+53.37 %) |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Sell | S | 6.85 | 35,000 | 239,750 | 65,576 | 100.6 K to 65.6 K (-34.80 %) |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Buy | M | 1.41 | 35,000 | 49,350 | 100,576 | 65.6 K to 100.6 K (+53.37 %) |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Sell | S | 6.85 | 15,000 | 102,750 | 65,576 | 80.6 K to 65.6 K (-18.62 %) |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Buy | M | 4.91 | 15,000 | 73,650 | 80,576 | 65.6 K to 80.6 K (+22.87 %) |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Sell | S | 6.85 | 10,000 | 68,500 | 65,576 | 75.6 K to 65.6 K (-13.23 %) |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Buy | M | 4.91 | 10,000 | 49,100 | 75,576 | 65.6 K to 75.6 K (+15.25 %) |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Sell | S | 6.85 | 45,000 | 308,250 | 65,576 | 110.6 K to 65.6 K (-40.70 %) |
| Sep 13 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Buy | M | 5.29 | 45,000 | 238,050 | 110,576 | 65.6 K to 110.6 K (+68.62 %) |
| Sep 10 2018 | CYCC | Cyclacel Pharmaceu ... | Spiegel Robert J. | Director | Option Exercise | A | 1.43 | 8,576 | 12,264 | 8,576 | |
| Aug 15 2018 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
| Jul 02 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 2,095 | 0 | 65,576 | 63.5 K to 65.6 K (+3.30 %) |
| Jul 02 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 2,095 | 0 | 65,576 | 63.5 K to 65.6 K (+3.30 %) |
| Jun 20 2018 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | A | 1.10 | 20,000 | 22,000 | 20,000 | |
| May 17 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Option Exercise | A | 3.43 | 70,000 | 240,100 | 70,000 | |
| Mar 30 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 1,691 | 0 | 63,481 | 61.8 K to 63.5 K (+2.74 %) |
| Feb 13 2018 | SCMP | Sucampo Pharmaceut ... | Spiegel Robert J. | Director | Option Exercise | D | 10.30 | 10,000 | 103,000 | 0 | |
| Feb 13 2018 | SCMP | Sucampo Pharmaceut ... | Spiegel Robert J. | Director | Option Exercise | D | 16.23 | 20,000 | 324,600 | 0 | |
| Feb 13 2018 | SCMP | Sucampo Pharmaceut ... | Spiegel Robert J. | Director | Option Exercise | D | 14.04 | 30,000 | 421,200 | 0 | |
| Feb 13 2018 | SCMP | Sucampo Pharmaceut ... | Spiegel Robert J. | Director | Sell | D | 18.00 | 5,130 | 92,340 | 0 | 5.1 K to 0 (-100.00 %) |
| Jan 02 2018 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 3,993 | 0 | 61,790 | 57.8 K to 61.8 K (+6.91 %) |
| Oct 02 2017 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 3,297 | 0 | 57,797 | 54.5 K to 57.8 K (+6.05 %) |
| Jun 30 2017 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 2,595 | 0 | 54,500 | 51.9 K to 54.5 K (+5.00 %) |
| Jun 21 2017 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | A | 10.15 | 15,000 | 152,250 | 15,000 | |
| Jun 05 2017 | SCMP | Sucampo Pharmaceut ... | Spiegel Robert J. | Director | Option Exercise | A | 10.30 | 10,000 | 103,000 | 60,000 | |
| Jun 05 2017 | SCMP | Sucampo Pharmaceut ... | Spiegel Robert J. | Director | Grant | A | 0.00 | 5,130 | 0 | 14,930 | 9.8 K to 14.9 K (+52.35 %) |
| May 10 2017 | GERN | GERON CORP | Spiegel Robert J. | Director | Option Exercise | A | 2.63 | 50,000 | 131,500 | 50,000 | |
| Mar 31 2017 | GERN | GERON CORP | Spiegel Robert J. | Director | Grant | A | 0.00 | 3,166 | 0 | 51,905 | 48.7 K to 51.9 K (+6.50 %) |
| Jun 23 2016 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | A | 9.34 | 15,000 | 140,100 | 15,000 | |
| Jun 23 2016 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | A | 9.34 | 15,000 | 140,100 | 15,000 | |
| Jun 06 2016 | SCMP | Sucampo Pharmaceut ... | Spiegel Robert J. | Director | Grant | A | 0.00 | 9,800 | 0 | 9,800 | 0 to 9.8 K |
| May 19 2016 | GERN | GERON CORP | Spiegel Robert J. | Director | Option Exercise | A | 2.74 | 50,000 | 137,000 | 50,000 | |
| Jan 06 2016 | PTCT | PTC THERAPEUTICS, ... | Spiegel Robert J. | Chief Medical Offic ... | Option Exercise | A | 30.86 | 10,000 | 308,600 | 10,000 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | C | 0.00 | 14,409 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | C | 0.00 | 32,258 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Buy | J | 7.91 | 1,549 | 12,253 | 38,661 | 37.1 K to 38.7 K (+4.17 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Buy | P | 11.00 | 3,000 | 33,000 | 37,112 | 34.1 K to 37.1 K (+8.79 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Buy | C | 0.00 | 10,533 | 0 | 34,112 | 23.6 K to 34.1 K (+44.67 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Buy | C | 0.00 | 23,579 | 0 | 23,579 | 0 to 23.6 K |
| Jun 02 2015 | SCMP | Sucampo Pharmaceut ... | Spiegel Robert J. | Director | Option Exercise | A | 16.23 | 20,000 | 324,600 | 50,000 | |
| May 19 2015 | GERN | GERON CORP | Spiegel Robert J. | Director | Option Exercise | A | 3.88 | 35,000 | 135,800 | 35,000 | |
| Mar 13 2015 | PTCT | PTC THERAPEUTICS, ... | Spiegel Robert J. | Chief Medical Offic ... | Sell | S | 75.95 | 2 | 152 | 3,239 | 3.2 K to 3.2 K (-0.06 %) |
| Mar 13 2015 | PTCT | PTC THERAPEUTICS, ... | Spiegel Robert J. | Chief Medical Offic ... | Sell | S | 75.10 | 1,028 | 77,203 | 3,241 | 4.3 K to 3.2 K (-24.08 %) |
| May 25 2010 | CAPS | Capstone Therapeut ... | Spiegel Robert J. | Director | Option Exercise | A | 0.82 | 50,000 | 41,000 | 50,000 |
Page: 1